ONC
BeOne Medicines Ltd.
NASDAQ · Healthcare · Medical - Pharmaceuticals · US
$358.26
−1.22%Year over year
Reported trailing growth
- Revenue
- +34.3%
- EBITDA
- +884.9%
- EBIT
- +1016.7%
- EPS
- +4547.4%
- Free cash flow
- +653.9%
- Operating cash flow
- +195.2%
Forward estimates
Based on analyst estimates
- Revenue
- +17.8%
- EBITDA
- +19.1%
- EPS
- -89.7%
Three-year CAGR
- Revenue
- +55.7%
- EBITDA
- +270.7%
- EBIT
- +178.7%
- Net income
- +144.5%
- EPS
- +652.3%
- Free cash flow
- +240.6%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026